As you may remember from previous posts, my HCT has been creeping steadily up. It looked initially like 175mcg Besremi was going to work, but the last two CBCs done outside of my hematology office indicate otherwise.
02/22/24 HGB=14.6, HCT=45.6, NEUT=1.19, LYMPH=0.73
03/19/24 HGB=15.5, HCT=47.3, NEUT=0.99, LYMPH=0.69
With NEUT<1.00, it is not viable to increase the Besremi dose. Per the previous plan I made with my MPN care team, I will arrange for a therapeutic phlebotomy. This will be the first phlebotomy since January 2023 and only the second phlebotomy since I started on the IFNs in May 2021. I consider that an acceptable response, though I would prefer to be phlebotomy-free. This is an example of where we must make rational risk/benefit decisions when managing an MPN. While I would prefer to increase the Besremi dose, it would not be in my best interests.
I am planning to keep the Besremi dose at 175mcg unless my MPN care team advises otherwise. I expect we will give it a bit of time to see if the NEUT comes back up above 1.00. If necessary, we will drop the dose back down to 150mcg. My primary treatment goal is to ensure quality of life as I define it. This approach is the best way to ensure that outcome.
The last A1C, glucose results indicate prediabetes may be progressing. These are the highest numbers I have had, though I have hovered above and below the limit for prediabetes for 10 years.
10/05/23 A1C=5.9, GLUC=123 (A1C Ref Range = 4.6-5.6)
02/22/24 A1C=5.5, GLUC=111.2
03/19/24 A1C=5.7, GLUC=117
Numbers have reduced slightly, but still higher than they have ever been. I do not believe this is related to Besremi due to my history prior to starting on the IFNs. I had my annual appointment with the endocrinologist in February. He does not advise any action other than healthy diet, exercise, and continue with weight loss. I have lost about 5 pounds in the last month, so that is moving in the right direction. I will meet with my PCP next week to review the plan.
In somewhat better news, I met with my cardiologist. I have had no incidents of tachycardia since June 2023. I am very pleased about that. Hopefully that trend will continue. As an interesting side note, the cardiologist agrees that systemic inflammation (from JAK2/NF1 mutations) plays a role in cardiovascular and other medical issues.
The only other news is that I succeeded in getting the Durolane injections into my knees. It took a bit to access the treatment through Medicare, but persistence overcame resistance. I am back up to full speed and able to exercise without problems.
That is all for now. A few more interesting health learning opportunities and on the whole success managing the PV and other health conditions. I am blessed to have an excellent care team to help manage everything. They listen to their patients and respect the patient’s ability to make decisions about their own care. They provide many outstanding examples of how shared decision-making works.
Wishing all of you all the best and success on your journeys.